Details of the Drug Combination

General Information of Drug Combination (ID: DCAA4S6)

Drug Combination Name
Nitroglycerin Nitroglycerin
Indication
Disease Entry Status REF
Rectal Cancer Phase 1 [1]
Component Drugs Nitroglycerin   DMQ2491 Nitroglycerin   DMQ2491
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nitroglycerin
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [2]
Diabetic foot ulcer BD54 Approved [3]
Nitroglycerin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Soluble guanylate cyclase (GCS) TT23PYC GCYA1_HUMAN; GCYB1_HUMAN Modulator [4]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Activator [3]
------------------------------------------------------------------------------------
Indication(s) of Nitroglycerin
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [2]
Diabetic foot ulcer BD54 Approved [3]
Nitroglycerin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Soluble guanylate cyclase (GCS) TT23PYC GCYA1_HUMAN; GCYB1_HUMAN Modulator [4]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Activator [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01407107) Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7053).
3 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
4 Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.